CClinicalTrials.gg
TerminatedNCT03867695SERRATHORUpdated Jul 10, 2026

SERRATHOR TRIAL : Interest of the Novel Serratus Plane Block in Post Operative Analgesia After Video-Assisted Thoracoscopic Lobectomy

An interventional study of Ropivacaine and sterile saline in Video Assisted Thoracoscopic Surgery, Lobectomy and Pain Post Operative, sponsored by University Hospital, Strasbourg, France. Terminated at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Supportive care

Why this study was terminated
The early termination of this study is justified by changes in the recommendations. Specifically, a paravertebral block-that is, a regional anesthesia technique-is now recommended. Consequently, subject recruitment has been halted.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Pain after thoracic surgery remains a challenge for anesthetists. Although VATS for lobectomy is associated with fewer complications compared to thoracotomy, pain after VATS needs to be treated with opioids. Opioids may lead to PONV, respiratory depression, sedation and pruritus. As part of multimodal analgesia and opioids sparing, several local regional techniques has been described: paravertebral block, thoracic epidural analgesia, intercostal block. To date, there is no gold standard for regional anesthesia after VATS.

Serratus plane block is a local regional technique, recently described for analgesia after breast surgery and ribs fracture. In our hospital center, since 2016, we used the Serratus plane block for patients scheduled for lobectomy VATS : a local retrospective trial showed that SPB was associated with a lower consumption of morphine.

The purpose of this randomized controlled double blinded study is to evaluate the analgesic effect of the Serratus plane block, added to a general anesthesia on post operative pain control after VATS lobectomy.

02

Conditions studied

  • Video Assisted Thoracoscopic Surgery
  • Lobectomy
  • Pain Post Operative
  • Regional Anesthesia

Browse trials for

Keywords

  • Serratus plane block
  • Analgesia after VATS
  • Lobectomy VATS
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients undergoing lobectomy VATS
  • Older > 18 years
  • Patients who meet criteria of ASA 1 to 3 class

Exclusion criteria

Exclusion criteria:

  • Patient's refusal to participate in the study
  • Psychiatric disorder (impossibility to collect the informed consent)
  • Patient under juridical protection
  • On going an other study
  • Non balanced epilepsy
  • 3 grade auriculo-ventricular heart block without pacing
  • Severe hepatocellular insufficiency
  • Anti arrhythmic treatment : class III of the Vaughan William's classification
  • Pregnant patient or/and breastfeeding
  • History of opioid abuse
  • Allergy to local anesthetic drug or opioids
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Serratus Block

    At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered. Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle. Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product.

    Drug: Ropivacaine

  • Placebo comparator
    Placebo Block - Control Group

    Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle. Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product.

    Drug: sterile saline

Interventions

  • DrugRopivacaine

    At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.

  • Drugsterile saline

    Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution

06

What researchers measure

Primary outcomes

  1. Total intravenous morphine consumption (mg) in the PACU and department.

    Including the dose of titration while the patient is in PACU and PCA up to 24h postoperatively.

    Time frame: 24 hours

07

Study locations

1 site
  • Les Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03867695
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Mar 8, 2019
Start date
Sep 3, 2019
Primary completion
Oct 30, 2020
Completion
Oct 30, 2020
Last update
Jul 10, 2026

Study contacts

Bob HEGER
principal investigator · Les Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion